Rock Creek Pharmaceuticals Inc  

(Public, NASDAQ:RCPI)   Watch this stock  
Find more results for NASDAQ:STSI
-0.030 (-3.25%)
Oct 6 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 0.85 - 0.92
52 week 0.76 - 9.25
Open 0.92
Vol / Avg. 0.00/155,571.00
Mkt cap 10.00M
P/E     -
Div/yield     -
EPS -1.60
Shares 10.87M
Beta 1.38
Inst. own 11%
Nov 9, 2015
Q3 2015 Rock Creek Pharmaceuticals Inc Earnings Release (Estimated) Add to calendar
Sep 16, 2015
Rock Creek Pharmaceuticals Inc at EBD Group BioPharm America
Sep 10, 2015
Rock Creek Pharmaceuticals Inc at Rodman & Renshaw Global Investment Conference
Aug 10, 2015
Q2 2015 Rock Creek Pharmaceuticals Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '15) 2014
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -67.94% -333.34%
Return on average equity - -
Employees 10 -
CDP Score - -


2040 Whitfield Avenue, Suite 300
United States - Map
+1-804-5271970 (Phone)
+1-302-6365454 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Rock Creek Pharmaceuticals, Inc. is a pharmaceutical development company. The Company is focused on the discovery, development, and commercialization of therapies for chronic inflammatory disease, neurologic disorders, and behavioral health utilizing its compounds. Its development activities are focused on its lead compound, anatabine citrate. Anatabine citrate is a small molecule, cholinergic agonist, which exhibits anti-inflammatory pharmacological characteristics, with a mechanism of action distinct from other anti-inflammatory drugs available, such as biologics, steroids and non-steroidal anti-inflammatories. Its lead compounds have shown preclinical in vitro and in vivo ability to modulate the expression of specific inflammatory molecules considered relevant to many chronic inflammatory disease states.

Officers and directors

Michael John Mullan Ph.D., M.D. Chairman of the Board, Office of President, Chief Executive Officer
Age: 58
Bio & Compensation  - Reuters
William L. McMahon Interim Chief Financial Officer, Treasurer
Age: 62
Bio & Compensation  - Reuters
Theodore Jenkins Secretary, Vice President - Corporate Strategy & Development
Bio & Compensation  - Reuters
Lee M. Canaan Independent Director
Age: 58
Bio & Compensation  - Reuters
Sunitha Chundru Samuel Independent Director
Age: 38
Bio & Compensation  - Reuters
Scott P. Sensenbrenner Independent Director
Age: 45
Bio & Compensation  - Reuters